NL1003275C2 - Inrichting voor het afgeven van een pijnstillend geneesmiddel door middel van elektrotransport. - Google Patents

Inrichting voor het afgeven van een pijnstillend geneesmiddel door middel van elektrotransport. Download PDF

Info

Publication number: NL1003275C2
Authority: NL; Netherlands
Prior art keywords: fentanyl; electrotransport; salt; drug; sufentanil
Prior art date: 1995-06-05

Application number

NL1003275A

Other languages

English (en)

Dutch (nl)

Other versions

NL1003275A1 (nl

Inventor

Joseph Brad Phipps

Original Assignee

Alza Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-05

Filing date

1996-06-05

Publication date

1999-02-09

1996-06-05 Application filed by Alza Corp filed Critical Alza Corp

1996-12-06 Publication of NL1003275A1 publication Critical patent/NL1003275A1/xx

1999-02-09 Application granted granted Critical

1999-02-09 Publication of NL1003275C2 publication Critical patent/NL1003275C2/nl

Links

229940035676 analgesics Drugs 0.000 title claims description 12
239000000730 antalgic agent Substances 0.000 title claims description 11
238000003860 storage Methods 0.000 claims description 59
GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical class C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 claims description 49
239000003814 drug Substances 0.000 claims description 46
229940079593 drug Drugs 0.000 claims description 41
230000004907 flux Effects 0.000 claims description 34
239000000243 solution Substances 0.000 claims description 27
239000000017 hydrogel Substances 0.000 claims description 26
PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical class C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims description 19
150000003839 salts Chemical class 0.000 claims description 19
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
238000012377 drug delivery Methods 0.000 claims description 13
239000007864 aqueous solution Substances 0.000 claims description 11
239000003792 electrolyte Substances 0.000 claims description 5
230000001419 dependent effect Effects 0.000 claims description 4
IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 73
229960002428 fentanyl Drugs 0.000 description 70
229960004739 sufentanil Drugs 0.000 description 29
210000003491 skin Anatomy 0.000 description 24
239000000203 mixture Substances 0.000 description 22
230000037317 transdermal delivery Effects 0.000 description 16
238000009472 formulation Methods 0.000 description 15
239000000499 gel Substances 0.000 description 15
229920002451 polyvinyl alcohol Polymers 0.000 description 15
239000004372 Polyvinyl alcohol Substances 0.000 description 14
230000000202 analgesic effect Effects 0.000 description 14
239000003795 chemical substances by application Substances 0.000 description 14
239000011159 matrix material Substances 0.000 description 12
-1 for example Chemical class 0.000 description 11
229910052709 silver Inorganic materials 0.000 description 11
239000004332 silver Substances 0.000 description 11
230000001070 adhesive effect Effects 0.000 description 9
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 8
239000000853 adhesive Substances 0.000 description 8
238000009792 diffusion process Methods 0.000 description 7
239000000463 material Substances 0.000 description 7
238000000034 method Methods 0.000 description 7
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
239000000872 buffer Substances 0.000 description 6
229920001477 hydrophilic polymer Polymers 0.000 description 5
239000007788 liquid Substances 0.000 description 5
229960005455 polacrilin Drugs 0.000 description 5
MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
208000002193 Pain Diseases 0.000 description 4
239000002253 acid Substances 0.000 description 4
230000008901 benefit Effects 0.000 description 4
230000007423 decrease Effects 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
210000004400 mucous membrane Anatomy 0.000 description 4
230000036407 pain Effects 0.000 description 4
230000036470 plasma concentration Effects 0.000 description 4
229910021607 Silver chloride Inorganic materials 0.000 description 3
125000002091 cationic group Chemical group 0.000 description 3
238000004132 cross linking Methods 0.000 description 3
230000000694 effects Effects 0.000 description 3
210000002615 epidermis Anatomy 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
210000000282 nail Anatomy 0.000 description 3
229940127240 opiate Drugs 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
239000011148 porous material Substances 0.000 description 3
229920005989 resin Polymers 0.000 description 3
239000011347 resin Substances 0.000 description 3
HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000002562 thickening agent Substances 0.000 description 3
238000013271 transdermal drug delivery Methods 0.000 description 3
239000000080 wetting agent Substances 0.000 description 3
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
230000036592 analgesia Effects 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
150000001860 citric acid derivatives Chemical class 0.000 description 2
238000002716 delivery method Methods 0.000 description 2
229920001971 elastomer Polymers 0.000 description 2
239000013536 elastomeric material Substances 0.000 description 2
230000005684 electric field Effects 0.000 description 2
229960004379 fentanyl hydrochloride Drugs 0.000 description 2
150000003840 hydrochlorides Chemical class 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
229920003145 methacrylic acid copolymer Polymers 0.000 description 2
230000005012 migration Effects 0.000 description 2
238000013508 migration Methods 0.000 description 2
238000002156 mixing Methods 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
LHCBOXPPRUIAQT-UHFFFAOYSA-N n-phenyl-n-[1-(2-phenylethyl)piperidin-4-yl]propanamide;hydrochloride Chemical compound Cl.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 LHCBOXPPRUIAQT-UHFFFAOYSA-N 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000035515 penetration Effects 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
239000002861 polymer material Substances 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
230000000007 visual effect Effects 0.000 description 2
238000005303 weighing Methods 0.000 description 2
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical group C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
241001535291 Analges Species 0.000 description 1
239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
229920002907 Guar gum Polymers 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229920003091 Methocel™ Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229920002367 Polyisobutene Polymers 0.000 description 1
208000004550 Postoperative Pain Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 1
206010040829 Skin discolouration Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
OJCZPLDERGDQRJ-UHFFFAOYSA-N Sufentanil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 OJCZPLDERGDQRJ-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
238000013459 approach Methods 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
229920001429 chelating resin Polymers 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
239000002131 composite material Substances 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000002845 discoloration Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000000806 elastomer Substances 0.000 description 1
238000005370 electroosmosis Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
239000005038 ethylene vinyl acetate Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000000665 guar gum Substances 0.000 description 1
229960002154 guar gum Drugs 0.000 description 1
235000010417 guar gum Nutrition 0.000 description 1
239000003906 humectant Substances 0.000 description 1
229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000007726 management method Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
239000004084 narcotic analgesic agent Substances 0.000 description 1
239000002547 new drug Substances 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920006112 polar polymer Polymers 0.000 description 1
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
238000003825 pressing Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
239000008213 purified water Substances 0.000 description 1
239000005871 repellent Substances 0.000 description 1
238000000518 rheometry Methods 0.000 description 1
230000008591 skin barrier function Effects 0.000 description 1
230000037370 skin discoloration Effects 0.000 description 1
231100000245 skin permeability Toxicity 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
210000000434 stratum corneum Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
229960001204 sufentanil citrate Drugs 0.000 description 1
230000001839 systemic circulation Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
- A61N1/0448—Drug reservoir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Biomedical Technology (AREA)
Radiology & Medical Imaging (AREA)
Pain & Pain Management (AREA)
Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Electrotherapy Devices (AREA)

NL1003275A 1995-06-05 1996-06-05 Inrichting voor het afgeven van een pijnstillend geneesmiddel door middel van elektrotransport. NL1003275C2 (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US46390495A	1995-06-05	1995-06-05
US46390495		1995-06-05

Publications (2)

Publication Number	Publication Date
NL1003275A1 NL1003275A1 (nl)	1996-12-06
NL1003275C2 true NL1003275C2 (nl)	1999-02-09

Family

ID=23841755

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL1003275A NL1003275C2 (nl)	1995-06-05	1996-06-05	Inrichting voor het afgeven van een pijnstillend geneesmiddel door middel van elektrotransport.

Country Status (23)

Country	Link
US (1)	US20090264855A1 (de)
EP (1)	EP0939659B1 (de)
JP (3)	JPH11506683A (de)
KR (1)	KR100449943B1 (de)
CN (1)	CN1118307C (de)
AT (2)	ATE442184T1 (de)
AU (1)	AU699718B2 (de)
BE (1)	BE1011002A3 (de)
BR (1)	BR9609138B1 (de)
CA (1)	CA2219406C (de)
CH (1)	CH690562A5 (de)
DE (1)	DE19681421B4 (de)
DK (1)	DK0939659T3 (de)
ES (1)	ES2331981T3 (de)
FR (1)	FR2734728B1 (de)
GB (1)	GB2317569B (de)
GR (1)	GR1003095B (de)
IE (1)	IE960375A1 (de)
IT (1)	IT1285398B1 (de)
NL (1)	NL1003275C2 (de)
SE (1)	SE518313C2 (de)
WO (1)	WO1996039223A1 (de)
ZA (1)	ZA964320B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6246904B1 (en) *	1996-12-17	2001-06-12	Alza Corporation	Electrotransport drug delivery reservoirs containing inert fillers
AU766913B2 (en)	1998-11-02	2003-10-23	Alza Corporation	Electrotransport device including a compatible antimicrobial agent
JP4898073B2 (ja)	2000-07-31	2012-03-14	ニュコメデダンマルクアンパーツセルスカブ	鼻内投与用フェンタニル組成物
DE60227938D1 (de)	2001-04-04	2008-09-11	Alza Corp	Transdermales verabreichungsgerät mittels elektrotransport mit einer kompatiblen antimikrobiellen reservoir-lösung
DE10141650C1 (de)	2001-08-24	2002-11-28	Lohmann Therapie Syst Lts	Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
GB0300531D0 (en)	2003-01-10	2003-02-12	West Pharm Serv Drug Res Ltd	Pharmaceutical compositions
JP2007229003A (ja) *	2006-02-27	2007-09-13	Transcutaneous Technologies Inc	イオントフォレーシス装置
JP2007244699A (ja) *	2006-03-16	2007-09-27	Transcutaneous Technologies Inc	イオントフォレーシス装置
CA2944660A1 (en)	2008-12-30	2010-07-08	Teva Pharmaceuticals International Gmbh	Electronic control of drug delivery system
US8961492B2 (en)	2009-02-12	2015-02-24	Incube Labs, Llc	System and method for controlling the iontophoretic delivery of therapeutic agents based on user inhalation
US8190252B2 (en)	2009-02-12	2012-05-29	Incube Labs, Llc	Iontophoretic system for transdermal delivery of active agents for therapeutic and medicinal purposes
US9008765B2 (en)	2009-02-12	2015-04-14	Incube Labs, Llc	System and method for biphasic transdermal iontophoretic delivery of therapeutic agents for the control of addictive cravings
WO2011044175A2 (en)	2009-10-06	2011-04-14	Incube Labs, Llc	Patch and patch assembly for iontophoretic transdermal delivery of active agents for therapeutic and medicinal purposes
US8685038B2 (en)	2009-12-07	2014-04-01	Incube Labs, Llc	Iontophoretic apparatus and method for marking of the skin
US8986279B2 (en)	2010-02-10	2015-03-24	Incube Labs, Llc	Methods and architecture for power optimization of iontophoretic transdermal drug delivery
CN103118738B (zh) *	2010-09-21	2015-06-24	皇家飞利浦电子股份有限公司	电极设备
CN103228318B (zh)	2010-11-23	2016-03-23	泰华制药国际有限公司	使用者激活的自包含共封装的离子透入给药系统
CN106955415B (zh) *	2011-03-24	2019-06-18	因卡伯实验室有限责任公司	用于治疗剂的两阶段经皮离子电渗递送的系统及方法
CN107376116A (zh) *	2017-07-31	2017-11-24	成都三乙医疗科技有限公司	高舒适度的电疗贴片

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1990003825A1 (en) *	1988-10-03	1990-04-19	Alza Corporation	Control membrane for electrotransport drug delivery
WO1991008795A2 (en) *	1989-12-14	1991-06-27	Alza Corporation	Improved iontophoretic delivery method
WO1993001807A1 (en) *	1991-07-24	1993-02-04	Alza Corporation	Transdermal delivery device
US5298017A (en) *	1992-12-29	1994-03-29	Alza Corporation	Layered electrotransport drug delivery system

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4141359A (en) *	1976-08-16	1979-02-27	University Of Utah	Epidermal iontophoresis device
US4856188A (en) *	1984-10-12	1989-08-15	Drug Delivery Systems Inc.	Method for making disposable and/or replenishable transdermal drug applicators
US5224928A (en) *	1983-08-18	1993-07-06	Drug Delivery Systems Inc.	Mounting system for transdermal drug applicator
US5135479A (en) *	1983-08-18	1992-08-04	Drug Delivery Systems, Inc.	Programmable control and mounting system for transdermal drug applicator
US4588580B2 (en) *	1984-07-23	1999-02-16	Alaz Corp	Transdermal administration of fentanyl and device therefor
US5135477A (en)	1984-10-29	1992-08-04	Medtronic, Inc.	Iontophoretic drug delivery
US4752285B1 (en)	1986-03-19	1995-08-22	Univ Utah Res Found	Methods and apparatus for iontophoresis application of medicaments
US4917676A (en) *	1986-11-20	1990-04-17	Ciba-Geigy Corporation	User-activated transdermal therapeutic system
US4906463A (en) *	1986-12-22	1990-03-06	Cygnus Research Corporation	Transdermal drug-delivery composition
US4878892A (en) *	1987-02-10	1989-11-07	Drug Delivery Systems Inc.	Electrolytic transdermal delivery of polypeptides
US4911707A (en) *	1987-02-13	1990-03-27	Ciba-Geigy Corporation	Monolithic user-activated transdermal therapeutic system
US4822802A (en) *	1987-02-24	1989-04-18	Alza Corporation	Method of fentanly administration for postoperative pain relief
US4931046A (en) *	1987-05-15	1990-06-05	Newman Martin H	Iontophoresis drug delivery system
EP0398960B1 (de) *	1988-01-21	1995-12-06	Massachusetts Institute Of Technology	Molekültransport durch gewebe mit der verwendung von elektroporation
US5169382A (en) *	1988-10-03	1992-12-08	Alza Corporation	Membrane for electrotransport transdermal drug delivery
US4927408A (en) *	1988-10-03	1990-05-22	Alza Corporation	Electrotransport transdermal system
US5006108A (en) *	1988-11-16	1991-04-09	Noven Pharmaceuticals, Inc.	Apparatus for iontophoretic drug delivery
US4891377A (en) *	1988-12-02	1990-01-02	Board Of Regents Acting For And On Behalf Of University Of Michigan	Transdermal delivery of the narcotic analgesics etorphine and analogs
US5320597A (en) *	1991-02-08	1994-06-14	Becton, Dickinson And Company	Device and method for renewing electrodes during iontophoresis
US5232448A (en) *	1989-12-05	1993-08-03	Prime Medical Products	Patient-controlled analgesia device
US5047007A (en) *	1989-12-22	1991-09-10	Medtronic, Inc.	Method and apparatus for pulsed iontophoretic drug delivery
US5125894A (en) *	1990-03-30	1992-06-30	Alza Corporation	Method and apparatus for controlled environment electrotransport
DK0521988T3 (da) *	1990-03-30	1996-04-29	Alza Corp	Anordning til iontoforetisk lægemiddeltilførsel
US5224927A (en) *	1990-11-01	1993-07-06	Robert Tapper	Iontophoretic treatment system
US5254081A (en) *	1991-02-01	1993-10-19	Empi, Inc.	Multiple site drug iontophoresis electronic device and method
US5246418A (en) *	1991-12-17	1993-09-21	Becton Dickinson And Company	Iontophresis system having features for reducing skin irritation
FR2687321B1 (fr) *	1992-02-14	1999-04-16	Elf Aquitaine	Dispositif d'ionophorese pour l'administration transcutanee d'une quantite totale donnee d'un principe actif a un sujet.
AU2286995A (en)	1994-04-08	1995-10-30	Alza Corporation	Electrotransport system with ion exchange competitive ion capture
US5879322A (en) *	1995-03-24	1999-03-09	Alza Corporation	Self-contained transdermal drug delivery device
US6216033B1 (en) *	1996-05-22	2001-04-10	Alza Corporation	Device for transdermal electrotransport delivery of fentanyl and sufentanil
EP0836511B1 (de) *	1995-06-05	2004-04-07	Alza Corporation	Vorrichtung zur transdermalen iontophoretischen verabreichung von fentanyl und sufentanil

1996
- 1996-05-28 IE IE960375A patent/IE960375A1/en not_active IP Right Cessation
- 1996-05-28 ZA ZA964320A patent/ZA964320B/xx unknown
- 1996-05-29 GR GR960100177A patent/GR1003095B/el not_active IP Right Cessation
- 1996-06-04 IT IT96TO000488A patent/IT1285398B1/it active IP Right Grant
- 1996-06-05 NL NL1003275A patent/NL1003275C2/nl not_active IP Right Cessation
- 1996-06-05 AT AT96919155T patent/ATE442184T1/de not_active IP Right Cessation
- 1996-06-05 FR FR9606914A patent/FR2734728B1/fr not_active Expired - Fee Related
- 1996-06-05 CN CN96194529A patent/CN1118307C/zh not_active Expired - Fee Related
- 1996-06-05 EP EP96919155A patent/EP0939659B1/de not_active Expired - Lifetime
- 1996-06-05 AU AU61565/96A patent/AU699718B2/en not_active Ceased
- 1996-06-05 WO PCT/US1996/009256 patent/WO1996039223A1/en not_active Ceased
- 1996-06-05 BR BRPI9609138-0A patent/BR9609138B1/pt not_active IP Right Cessation
- 1996-06-05 KR KR1019970708821A patent/KR100449943B1/ko not_active Expired - Fee Related
- 1996-06-05 AT AT0903796A patent/AT413489B/de not_active IP Right Cessation
- 1996-06-05 ES ES96919155T patent/ES2331981T3/es not_active Expired - Lifetime
- 1996-06-05 CH CH02792/97A patent/CH690562A5/de not_active IP Right Cessation
- 1996-06-05 DK DK96919155T patent/DK0939659T3/da active
- 1996-06-05 BE BE9600505A patent/BE1011002A3/fr not_active IP Right Cessation
- 1996-06-05 JP JP9501614A patent/JPH11506683A/ja not_active Withdrawn
- 1996-06-05 CA CA2219406A patent/CA2219406C/en not_active Expired - Fee Related
- 1996-06-05 DE DE19681421T patent/DE19681421B4/de not_active Expired - Fee Related
- 1996-06-05 GB GB9725546A patent/GB2317569B/en not_active Expired - Fee Related
1997
- 1997-11-10 SE SE9704102A patent/SE518313C2/sv not_active IP Right Cessation
2005
- 2005-05-18 JP JP2005145273A patent/JP2005279288A/ja active Pending
2008
- 2008-04-04 JP JP2008097671A patent/JP2008178717A/ja not_active Withdrawn
- 2008-08-20 US US12/194,984 patent/US20090264855A1/en not_active Abandoned

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1990003825A1 (en) *	1988-10-03	1990-04-19	Alza Corporation	Control membrane for electrotransport drug delivery
WO1991008795A2 (en) *	1989-12-14	1991-06-27	Alza Corporation	Improved iontophoretic delivery method
WO1993001807A1 (en) *	1991-07-24	1993-02-04	Alza Corporation	Transdermal delivery device
US5298017A (en) *	1992-12-29	1994-03-29	Alza Corporation	Layered electrotransport drug delivery system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PRÉAT AND THYSMAN: "transdermal iontophoretic delivery of sufentanil", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 96, 1993, pages 189 - 196, XP000576958 *

Also Published As

Publication number	Publication date
SE518313C2 (sv)	2002-09-24
GR1003095B (el)	1999-03-22
BE1011002A3 (fr)	1999-03-02
AU699718B2 (en)	1998-12-10
ATA903796A (de)	2005-08-15
IT1285398B1 (it)	1998-06-03
CA2219406A1 (en)	1996-12-12
ATE442184T1 (de)	2009-09-15
SE9704102D0 (sv)	1997-11-10
GB2317569B (en)	1999-08-04
JPH11506683A (ja)	1999-06-15
CN1118307C (zh)	2003-08-20
FR2734728B1 (fr)	1997-10-17
FR2734728A1 (fr)	1996-12-06
JP2005279288A (ja)	2005-10-13
EP0939659A1 (de)	1999-09-08
JP2008178717A (ja)	2008-08-07
ITTO960488A0 (it)	1996-06-04
KR100449943B1 (ko)	2004-12-03
DK0939659T3 (da)	2009-11-23
ITTO960488A1 (it)	1997-12-04
ZA964320B (en)	1997-01-13
AU6156596A (en)	1996-12-24
EP0939659B1 (de)	2009-09-09
DE19681421B4 (de)	2009-04-09
CA2219406C (en)	2010-01-26
GB2317569A (en)	1998-04-01
DE19681421T1 (de)	1998-07-23
AT413489B (de)	2006-03-15
US20090264855A1 (en)	2009-10-22
SE9704102L (sv)	1997-11-10
GB9725546D0 (en)	1998-02-04
BR9609138A (pt)	1999-02-17
KR19990022341A (ko)	1999-03-25
CN1187141A (zh)	1998-07-08
ES2331981T3 (es)	2010-01-21
GR960100177A (el)	1997-02-28
CH690562A5 (de)	2000-10-31
BR9609138B1 (pt)	2008-11-18
IE960375A1 (en)	1996-12-11
NL1003275A1 (nl)	1996-12-06
WO1996039223A1 (en)	1996-12-12

Legal Events

Date	Code	Title	Description
1997-02-03	AD1A	A request for search or an international type search has been filed
1998-12-01	RD2N	Patents in respect of which a decision has been taken or a report has been made (novelty report)	Effective date: 19981006
1999-04-01	PD2B	A search report has been drawn up
2012-01-11	V1	Lapsed because of non-payment of the annual fee	Effective date: 20120101

Publication	Publication Date	Title
NL1003274C2 (nl)	1998-11-03	Inrichting voor het door middel van een elektrotransport transdermaal afgeven van fentanyl en sufentanil.
NL1003273C2 (nl)	1998-10-20	Inrichting voor transdermale afgifte van fentanyl en sufentanil door middel van elektrotransport.
NL1003275C2 (nl)	1999-02-09	Inrichting voor het afgeven van een pijnstillend geneesmiddel door middel van elektrotransport.
US6216033B1 (en)	2001-04-10	Device for transdermal electrotransport delivery of fentanyl and sufentanil
US7018370B2 (en)	2006-03-28	Device for transdermal electrotransport delivery of fentanyl and sufentanil
US20080009782A1 (en)	2008-01-10	Methods and Devices for Transdermal Electrotransport Delivery of Lofentanil and Carfentanil
CA2656086A1 (en)	2008-12-31	Methods and devices for transdermal electrotransport delivery of lofentanil and carfentanil